Ischemic Stroke – Landscape & Forecast – Disease Landscape & Forecast (G7)

Acute ischemic stroke (AIS) affects millions of individuals across G7 countries, according to Clarivate Epidemiology’s tracked lifetime and 12-month prevalent cohorts. As a time-critical emergency, AIS necessitates rapid intervention to preserve salvageable brain tissue. The standard of care includes IV thrombolysis within 4.5 hours and mechanical thrombectomy for eligible large-vessel occlusions. Roche / Genentech’s tenecteplase has expanded reperfusion options, offering a longer half-life and single-bolus administration compared with alteplase. Despite this advance, further innovation in the management of AIS is sorely needed to bring neuroprotective/restorative/reparative and other new therapies to AIS patients to optimize their functional recovery. However, few strategies in this arena have achieved clear clinical proof-of-concept, and trial failures have been the historical norm. Nonetheless, the AIS pipeline is large, active, and diverse regarding mechanisms of action, and the field is focused on advancing trial design.

Questions answered

• How has the adoption of tenecteplase impacted AIS treatment in the United States and Europe?
• Which pharmacotherapies designed to be complementary to thrombolysis and/or thrombectomy to improve AIS outcomes hold the most promise according to key opinion leaders? What minimum levels of efficacy, safety, ease of use, and cost-effectiveness would be required for these therapies to meaningfully impact AIS treatment practice?
• What factors might limit the uptake of new neuroprotective or reparative agents?
• Is late-window thrombolysis a promising strategy to expand the addressable AIS market?
• What are the key unmet needs and opportunities in AIS, and can branded innovation credibly create value?

Geography: United States, EU5, Japan

Primary research: Country-specific interviews with 14 thought-leading neurologists; survey data collected for this and other Clarivate research

Epidemiology: Total, diagnosed, and drug-treated ischemic stroke events

Drug treatments: Coverage of key current and late-phase emerging therapies

Forecast: 10-year, annualized, drug-level sales and patient share of key AIS therapies through 2034, segmented by brands/generics.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.